DE3023813A1 - Arzneimittel - Google Patents

Arzneimittel

Info

Publication number
DE3023813A1
DE3023813A1 DE3023813A DE3023813A DE3023813A1 DE 3023813 A1 DE3023813 A1 DE 3023813A1 DE 3023813 A DE3023813 A DE 3023813A DE 3023813 A DE3023813 A DE 3023813A DE 3023813 A1 DE3023813 A1 DE 3023813A1
Authority
DE
Germany
Prior art keywords
msh
peptides
acth
endorphin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE3023813A
Other languages
German (de)
English (en)
Inventor
Hendrik Marie Heesch Greven
David de Bilthoven Wied
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Priority to DE3023813A priority Critical patent/DE3023813A1/de
Priority to PCT/EP1981/000075 priority patent/WO1982000031A1/en
Priority to NL8120190A priority patent/NL8120190A/nl
Priority to CH1218/82A priority patent/CH647410A5/de
Priority to JP56501930A priority patent/JPS57500829A/ja
Priority to GB8201463A priority patent/GB2086396B/en
Priority to AU72268/81A priority patent/AU542296B2/en
Priority to ZA814055A priority patent/ZA814055B/xx
Priority to US06/275,049 priority patent/US4410511A/en
Priority to FR8112213A priority patent/FR2485374A1/fr
Priority to IT67878/81A priority patent/IT1144816B/it
Priority to CA000380521A priority patent/CA1147654A/en
Priority to BE0/205213A priority patent/BE889384A/fr
Publication of DE3023813A1 publication Critical patent/DE3023813A1/de
Priority to SE8200757A priority patent/SE8200757L/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE3023813A 1980-06-25 1980-06-25 Arzneimittel Withdrawn DE3023813A1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE3023813A DE3023813A1 (de) 1980-06-25 1980-06-25 Arzneimittel
PCT/EP1981/000075 WO1982000031A1 (en) 1980-06-25 1981-06-15 Biologically active peptides
NL8120190A NL8120190A (cg-RX-API-DMAC7.html) 1980-06-25 1981-06-15
CH1218/82A CH647410A5 (de) 1980-06-25 1981-06-15 Biologisch wirksame peptide enthaltende arzneimittel.
JP56501930A JPS57500829A (cg-RX-API-DMAC7.html) 1980-06-25 1981-06-15
GB8201463A GB2086396B (en) 1980-06-25 1981-06-15 Biologically active peptides
AU72268/81A AU542296B2 (en) 1980-06-25 1981-06-15 Biologically active peptides
ZA814055A ZA814055B (en) 1980-06-25 1981-06-16 Biologically active peptides
US06/275,049 US4410511A (en) 1980-06-25 1981-06-18 Biologically active peptides
FR8112213A FR2485374A1 (fr) 1980-06-25 1981-06-22 Peptides a activite biologique
IT67878/81A IT1144816B (it) 1980-06-25 1981-06-24 Composizione farmaceutica contenente un peptide biologicamente attivo
CA000380521A CA1147654A (en) 1980-06-25 1981-06-24 Biologically active peptides
BE0/205213A BE889384A (fr) 1980-06-25 1981-06-25 Peptides a activite biologique
SE8200757A SE8200757L (sv) 1980-06-25 1982-02-10 Biologiskt aktiva peptider

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3023813A DE3023813A1 (de) 1980-06-25 1980-06-25 Arzneimittel

Publications (1)

Publication Number Publication Date
DE3023813A1 true DE3023813A1 (de) 1982-01-21

Family

ID=6105445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3023813A Withdrawn DE3023813A1 (de) 1980-06-25 1980-06-25 Arzneimittel

Country Status (14)

Country Link
US (1) US4410511A (cg-RX-API-DMAC7.html)
JP (1) JPS57500829A (cg-RX-API-DMAC7.html)
AU (1) AU542296B2 (cg-RX-API-DMAC7.html)
BE (1) BE889384A (cg-RX-API-DMAC7.html)
CA (1) CA1147654A (cg-RX-API-DMAC7.html)
CH (1) CH647410A5 (cg-RX-API-DMAC7.html)
DE (1) DE3023813A1 (cg-RX-API-DMAC7.html)
FR (1) FR2485374A1 (cg-RX-API-DMAC7.html)
GB (1) GB2086396B (cg-RX-API-DMAC7.html)
IT (1) IT1144816B (cg-RX-API-DMAC7.html)
NL (1) NL8120190A (cg-RX-API-DMAC7.html)
SE (1) SE8200757L (cg-RX-API-DMAC7.html)
WO (1) WO1982000031A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA814055B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345358A1 (de) * 1983-12-15 1985-06-27 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches mittel zur behandlung von fehlfunktionen des menschlichen diencephalon und/oder der hypophyse, insbesondere der multiplen sklerose
EP0146113A3 (de) * 1983-12-15 1987-08-19 Dieter Aderhold Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut
IT1218472B (it) * 1985-08-30 1990-04-19 Alfio Bertolini Composizioni farmaceutiche comprendenti acht (1-24) per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
GB2269821B (en) * 1992-08-08 1996-06-05 Shanghai Inst Biochemistry Memory enhancing peptides and pharmaceutical compositions containing them
US10188704B2 (en) 2015-05-18 2019-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130980C (cg-RX-API-DMAC7.html) * 1960-06-03 1900-01-01
FR1405270A (fr) * 1963-05-20 1965-07-09 Ciba Geigy Procédé de préparation d'un polypeptide, à savoir de la beta-msh
CH523227A (de) * 1966-12-30 1972-05-31 Ciba Geigy Ag Verfahren zur Herstellung neuer Peptidamide mit ACTH-Wirkung

Also Published As

Publication number Publication date
CA1147654A (en) 1983-06-07
US4410511A (en) 1983-10-18
GB2086396A (en) 1982-05-12
GB2086396B (en) 1983-10-12
BE889384A (fr) 1981-12-28
AU7226881A (en) 1982-01-19
SE8200757L (sv) 1982-02-10
NL8120190A (cg-RX-API-DMAC7.html) 1982-05-03
FR2485374B1 (cg-RX-API-DMAC7.html) 1984-11-30
FR2485374A1 (fr) 1981-12-31
AU542296B2 (en) 1985-02-14
IT1144816B (it) 1986-10-29
ZA814055B (en) 1982-07-28
IT8167878A0 (it) 1981-06-24
CH647410A5 (de) 1985-01-31
WO1982000031A1 (en) 1982-01-07
JPS57500829A (cg-RX-API-DMAC7.html) 1982-05-13

Similar Documents

Publication Publication Date Title
DE69418181T2 (de) Cytokine dämpfende substanzen
DE3587122T2 (de) Pharmakologisch aktive derivate von tryptophan und diese enthaltende pharmazeutische zusammensetzungen.
CH692477A5 (de) Zusammensetzung zur Stimulation von Wiederherstellungsvorgängen, enthaltend L-Lysil-L-Glutaminsäure.
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
EP0357978A1 (de) Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus
DE4037708A1 (de) Appetitzuegler und verfahren zu seiner anwendung
DE3522506C2 (cg-RX-API-DMAC7.html)
EP0490379A2 (de) Diaminosäurederivate und pharmazeutische Zusammensetzungen
DE2705514C3 (de) Nonapeptide und diese enthaltende Arzneimittel
CH661869A5 (de) Arzneimittel zur behandlung der ulkuskrankheit.
CH676425A5 (cg-RX-API-DMAC7.html)
DE3023813A1 (de) Arzneimittel
DE69322958T2 (de) Stabilisiertes somatotropin zur parenteralen verabreichung
CH649562A5 (de) Derivate des methionin-enzephalins.
DE69625913T2 (de) Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE2224130C3 (de) Tryptophanderivate und sie enthaltende pharmazeutische Zubereitungen
DE1518057C3 (de) Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität
DE3239710C2 (de) Peptid mit Nerven-regenerierenden Eigenschaften
DE2525064C2 (de) Arzneimittel mit Antiparkinson-Wirkung
EP0223850B1 (de) Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten
DE60130802T2 (de) Agonisten und antagonisten von urotensin-ii
DE69818020T2 (de) Beta-endorphin peptide zur behandlung von muskeldystrophien
DE2915158C2 (de) 2-Hydroxy-benzoat des 1-Benzyl-1H-indazol-3-yl-3-(dimethylamin)-propyläthers, Verfahren zu dessen Herstellung und Arzneimittel
EP0137294B1 (de) Gonadoliberin und Gonadoliberinagonisten zur Behandlung von Stoffwechselerkrankungen, die auf zu geringe Parathormonspiegel zurückzuführen sind

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee